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PODIUM SESSION III:
CANCER OUTCOMES RESEARCH
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DISCORDANT DIAGNOSES IN SARCOMA, GIST AND DESMOIDE TUMOUR IN
FRANCE: RESULTS FROM THE NETWORK RREPS
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A2, Ray Coquard I1, Ducimetière F1, Jean-Denis M1, Courrèges JB3, Mesli N2, Morelle M1,
Plommet N4, Blay JY1, Coindre JM3
1Leon Berard Cancer Centre, Lyon, France, 2Insitut Gustave Roussy, Villejuif, France, 3Institut
Bergonié, Bordeaux, France, 4University Lyon 2, Lyon, France
OBJECTIVES: Major discordant diagnoses may have strong impact on therapeutic
management. So, identification of major discordant diagnoses and predictive fac-
tors were conducted in sarcoma patients. METHODS: A multicenter analysis was
performed retrospectively from the prospective cohort of sarcoma patients. Inclu-
sion criteria were patients with a diagnosis of sarcoma in 2010 and with a second
opinion performed within the network RRePS (Réseau de Référence en Pathologie
des Sarcomes supported be the French NCI). Major discordant diagnoses were de-
fined as: sarcoma vs benign lesion, sarcoma vs malignant non sarcoma tumor,
gastrointestinal stromal tumors (GIST) vs non GIST, and desmoid tumor vs non
desmoid tumor. Patient and disease characteristics were described. Logistic regres-
sions were used in order to define predictive factors of major discordance.
RESULTS: 3621 patients were included in the study. 438 patients (12%) had a major
discordant diagnoses: sarcoma versus benign lesion (or conversely) in 155 patients
(58%); sarcoma instead of malignant non sarcoma tumor (or conversely) in 103
patients (24%); gastrointestinal stromal tumors (GIST) instead of non GIST in 48
patients (11%); desmoid tumor instead of non desmoid tumor in 28 patients (6%)
and other (4%). Major diagnostic discordances risks were higher (i) for malignant
non sarcoma tumors compared to GIST, liposarcoma, and other sarcoma histolog-
ical subtypes (p0.004); (ii) for patients who had a previous cancer (p0.03); (iii) for
limb localization compared to trunk (p0.004); (iv) when the second opinion was
requested by the initial pathologist (p0.01). CONCLUSIONS: This study reported
that sarcoma instead of benign lesion (or conversely) is the major discordant diag-
nosis in sarcoma patients implying that: (i) patients who should not be treated
received anticancer therapy; (ii) treatments are potentially delayed for patients
who should be rapidly treated. Economics evaluations are in progress in order to
advise health care administrators regarding systematic second reviews in the
management of sarcoma.
CA2
APPLYING A VALUE-BASED PRICE ACROSS DIFFERENT DISEASE AREAS
Wilson T, Kusel J, Brooks-Rooney C, Costello S
Costello Medical Consulting Ltd., Cambridge, UK
OBJECTIVES: Value-based pricing is currently a topic of much interest, and there is
wide-spread speculation as to how it will be implemented. The aim of this research
was to address the question as to how reimbursement bodies will consider value-
based pricing with regard to pharmaceuticals that can be used in multiple indica-
tions. Will there be separate prices, or an average price weighted by the population
size of each different population? If so, then would the price have to be re-assessed
each time the drug is approved for a new indication? METHODS: The National
Institute for Health and Clinical Excellence (NICE) in the UK was used as an exam-
ple to identify those therapies that have been appraised for multiple indications.
All NICE technology assessments for cancer treatments published since January
2005 were reviewed. Therapies used in different indications were identified and
ICERs from these appraisals were extracted. RESULTS: In total, 12 different treat-
ments were identified, spanning sixteen different indications within cancer. Of
these, five (cetuximab, docetaxel, imatinib, pemetrexed and trastuzumab) had IC-
ERs that were either side of the £30,000 per QALY threshold across different disease
areas. For example, the ICERs associated with cetuximab were found to vary from
£6,400 (squamous cell cancer of the head and neck) to £90,000 (colorectal cancer)
per QALY. These data suggest that there may be a large discrepancy when consid-
ering value-based pricing across different cancer populations. CONCLUSIONS:
Across indications, the ICERs for a single therapy were found to vary dramatically.
Considering that almost half of therapies identified had ICERs either side of the
£30,000 per QALY threshold, these results highlight the potential problem associ-
ated with labelling a pharmacologic treatment with a single value-based price.
Therefore, a single price may not be appropriate, and alternative methods should
be considered by reimbursement bodies.
CA3
USE OF HEALTH CARE ADMINISTRATIVE DATABASES TO ESTIMATE THE
BURDEN OF BREAST CANCER
Ciampichini R1, Furneri G1, Scalone L2, Cortesi PA2, Fornari C2, Madotto F2, Chiodini V2,
Mantovani LG3, Cesana G2
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OBJECTIVES: To assess the epidemiologic and economic burden of breast cancer
(BC) at any stage from a large population-based study. METHODS: Lombardy Re-
gion includes 9.9 million individuals. Eligible patients were identified through a
data warehouse (DENALI), which matches with a probabilistic linkage demo-
graphic, clinical and economic data of different Healthcare Administrative data-
bases. All female individuals who had a first hospital discharge with a IDC-9 CM
code 174.XX from 1st January 2004 were selected and followed up to 5 years. These
subjects were considered incident patients since they had no cause-specific hos-
pitalizations during 2000-2003 period. We calculated yearly incidence, mortality
and health care costs (hospitalizations, drugs and outpatient examinations/visits)
from the National Health Service’s perspective (NHS). RESULTS: A total of 50,868
eligible subjects (mean ageSD equals to 62.514.2) were identified. Incidence
patients were homogeneously distributed during the observational period: 20.5% in
2004, 20.1% in 2005, 19.7% in 2006, and 19.4% and 20.2 in 2007 and 2008. During the
2005-2008 period, the mean cost/patient-year for incident and prevalent cases
were: 12,973€ versus 4,428€ in 2005, 13,847€ versus 4,237€ in 2006, 14,742€ versus
4,400€ in 2007, 15,671€ versus 4,336€ in 2008. Of the total cost of incident patients,
hospitalizations were the driver (70%), with drugs and outpatient claims contrib-
uting to 16.3% and 16.2%, respectively. The driver of total costs in prevalent pa-
tients was drugs (41.1%), followed by hospitalizations and outpatients claims, con-
tributing to 37.1% and 21.8%, respectively. Overall 46.3 deaths/1,000 patients-year
were estimated with a probability of survival equals to 80% after 5 years from the
index date. CONCLUSIONS: The high epidemiological and economic burden of BC,
indicates the primary importance in monitoring the developing of the disease from
the NHS’s perspective. DENALI shows to be an efficient instrument combining
administrative databases to accurately estimate the burden of BC.
CA4
A COMPARISON OF PATIENT AND GENERAL-POPULATION UTILITY VALUES
FOR ADVANCED MELANOMA IN HEALTH ECONOMIC MODELLING
Batty A1, Winn B1, Lebmeier M2, Rowen D3, Lee D1
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OBJECTIVES: Health-related quality of life (HRQL) is an essential part of health
technology assessment; without this Quality Adjusted Life Years cannot be calcu-
lated. The objective of this study was to compare utilities calculated for patients
with advanced melanoma in the Phase III clinical trial for ipilimumab (MDX010-20)
with utilities produced by vignettes for advanced melanoma valued by the general
population. A comparison was also made between standard ‘progression-based’
utilities and those based on the time elapsed between the utility measurement and
the patient’s death. METHODS: Utilities from the trial were generated using the
EORTC-8D and SF-6D preference-based measures. Analyses by progression status
and time to death were conducted on patient-level data, and the prognostic value
of the methods was assessed. Patient-level results were then compared with the
utilities derived for progressive and non-progressive disease in a separate vignette
study. RESULTS: SF-6D and EORTC-8D showed a substantial decrease in utility in
the 180 days before the patient’s death (from 0.83 to 0.63 and from 0.66 to 0.51,
respectively), which is not consistent with the use of standard Markov progression-
based, health-state modelling. Time to death showed a lower Root Mean Squared
Error and higher R2when used to predict patient utility, demonstrating that they
produce a more accurate assessment of HRQL. Utilities taken from vignettes
showed a larger decrease on disease progression (from 0.77 to 0.59) than either the
generic SF-6D (from 0.64 to 0.62) or condition-specific EORTC-8D (from 0.80 to 0.76).
CONCLUSIONS: Although most oncology modelling is based around disease pro-
gression, this may not always be appropriate because the time to a patient’s death
appears to be a more accurate predictor of HRQL. This has implications for the
analysis of utility information in future cost-effectiveness studies as well as the
modelling methods used for oncology treatments and health technology assess-
ments.
PODIUM SESSION III:
CLINICAL OUTCOMES STUDY METHODOLOGICAL CHALLENGES
CL1
A MULTICRITERIA APPROACH FOR EVALUATING HEALTH-RELATED QUALITY-
OF-LIFE
Manolitzas P1, Krasoudakis A2, Grigoroudis E1, Matsatsinis N1, Archontakis G2
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OBJECTIVES:The main aim of this paper is to develop a new approach for analyzing
EQ-5D data based on the principles of multicriteria analysis. A data set of 73 pa-
tients after lumbar discectomy has been used in order to illustrate the applicability
of the model.METHODS:The proposed approach is an ordinal regression model for
measuring and analyzing EQ-5D data. The main objective of the method is the
aggregation of individual judgments into a collective value function. The proposed
approach provides a series of normalized average indices for each one of the di-
mensions of the EQ-5D instrument, as well as a set of perceptual maps. These
results include: average satisfaction, demanding, and improvement indices, as
well as action and improvement diagrams. RESULTS: The analysis of the sample
revealed a relatively high satisfaction level (84.65%) for the general health status
(VAS). Furthermore, the analysis of the EQ-5D questions shows that patients are
very satisfied regarding the dimensions of self-care (95.67%) and pain/discomfort
(95.63%). On the other hand, the lowest health status score refers to the dimension
of mobility (78.24%). The weights of these five dimensions are additional results of
the proposed method. Based on this particular sample, the results show that the
most important factor is the anxiety/depression (32.11%), following by the dimen-
sions of mobility (21.23%) and usual activities (19.16%). Combing these results, the
action diagram reveals a gap regarding the perceptions of these particular patients
and proposes mobility and anxiety/depression as critical health status dimensions.
CONCLUSIONS: The main advantage of the method is the ability to consider the
qualitative (ordinal) nature of the input information. In addition, the provided
results are rich enough to give a clearer view about the patient’s health status.
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OBJECTIVES: Economic evaluations in oncology require estimating survival bene-
fits which is used to obtain quality adjusted life years (QALYs) and incremental
cost-effectiveness ratios (ICERs). However, few guidelines exist on how survival
data should be analyzed and extrapolated to obtain full survival benefit for eco-
nomic evaluation. A recent NICE Decision Support Unit document details an algo-
rithm for selecting survival models for economic evaluations alongside clinical
trials. We use this algorithm and other published literature to demonstrate how
different models lead to varying survival estimates and how survival data can be
systematically assessed in a patient registry using patient-level data. METHODS:
Data from the National Cancer Institute’s Surveillance Epidemiology and End Re-
sults (SEER) were used. Surgical treatment for prostate cancer was used to illustrate
the methods, but the approach is transferrable to other cancers and treatment
strategies. Patients diagnosed with prostate cancer (PC) between 1991 and 2001
were included, the sample was limited to stage IV PC patients. Survival between
surgery and non-surgery group was estimated via Kaplan Meier, parametric and
semi-parametric methods. Several model fit criteria’s such as visual inspection,
log-cumulative hazard plots, Cox-Snell residuals, Akaike Information Criterion
(AIC), Bayesian Information Criterion (BIC) along with proportionality assumption
tests were used to select appropriate method and distribution. Observed and ex-
trapolated mean estimates were calculated and compared. RESULTS: Analysis in-
dicated that survival time and benefit differed based on the model selected. Our
case example demonstrated the best fit was with Weibull and exponential distri-
butions – however, consideration must also be given to the tail in any extrapolation
of the parametric distributions selected. CONCLUSIONS: Systematic analysis of
survival data is an important evaluation criterion by health technology assess-
ments. Selection of survival models must be justified using appropriate steps as
different models can yield varying estimates, and improper selection can translate
to incorrect estimation of QALYs and the resulting ICERs.
CL3
CALIBRATING BAYESIAN MULTIPLE TREATMENT COMPARISON META-
ANALYSIS WITH MULTIPLE COST-EFFECTIVENESS ACCEPTABILITY CURVES
Thorlund K1, Mills E2
1McMaster University, Hamilton, ON, Canada, 2University of Ottawa, Ottawa, ON, Canada
OBJECTIVES: To investigate the merits and challenges with calibrating Bayesian
multiple treatment comparison meta-analysis (MTC) with cost-effectiveness (CE)
analysis, in particular, construction of multiple cost-effectiveness acceptability
curves and cost-effectiveness frontiers. METHODS: We calibrated a Bayesian MTC
of pharmacotherapies for chronic obstructive pulmonary disease with a Bayesian
CE markov model. We simulated 10000 observations and derived multiple cost-
effectiveness acceptability curves for each of the treatments as well as the cost-
effectiveness frontier. We separately repeated the analyses based on pair-wise
meta-analysis estimates of treatment effectiveness. We compared the two ap-
proaches with respect to precision and inferred reasonable CE thresholds.
RESULTS: The MTC approach generally yielded higher precision, and thus, had
higher certainty surrounding the inferred CE thresholds. This was especially the
case for comparisons with treatments in the extended dominance region, but close
to the cost-effective treatments. CONCLUSIONS: Calibration of Bayesian multiple
treatment comparison meta-analysis and Bayesian multiple cost-effectiveness ac-
ceptability curves appears to improve precision compared with the conventional
approach.
CL4
MARGINAL STRUCTURAL MODELS USED IN ESTIMATING COST-EFFECTIVENESS
OF TIME-VARYING DRUG THERAPY USING ADIMISTRATIVE DATABASES. THE
CASE OF STATIN IN SECONDARY PREVENTION
Fornari C1, Valsecchi MG1, Galimberti S1, Madotto F1, Conti S1, Mantovani LG2, Cesana G1
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OBJECTIVES: Cost-effectiveness assessment using real-life data is important to
improve health care management. We applied marginal structural models (MSMs)
to evaluate cost-effectiveness of statin therapy and medication adherence in the
secondary prevention of acute myocardial infarction (AMI), using health care ad-
ministrative databases (HADs). METHODS: This is an observational longitudinal
study based on HADs of the national health care system in Lombardy, a region in
Northern Italy with about 9 millions of inhabitants. Patients hospitalized in 2003 for
their first episode of AMI were followed until December 31, 2008, collecting data on
health care services and vital status. Persistence and adherence to statin were
measured as time-dependent variables. We adopted a net-benefit regression ap-
proach with related acceptability curves, using direct medical costs and gained
life-years as outcomes. MSMs accounted for the dynamic interactive effects be-
tween treatment and the time-varying confounders, i.e. non-fatal cardiovascular
(CV) events and others CV therapies. RESULTS: A total of 11,706 individuals (65%
men) with a mean age of 70 years, were hospitalized for their first AMI during 2003.
26% of patients died during a median follow-up time of 5 years. The mean annul
total cost per patient was €4,348 (95%CI: 4,264-4,408), 59% of which was attributable
to CV diagnosis. Statin reduced the risk of death and medication adherence af-
fected risk reduction. The incremental net-benefit of statin therapy was positive
for values of willingness to pay (WTP) equal or greater than €0. The probability
that statin therapy was cost-effective was 50% for WTP equal to €0 and about
75% for values equal or greater than €250. Medication adherence influenced
cost-effectiveness. CONCLUSIONS: MSMs can be used in economic health care
evaluations to account for time-varying confounding, trying to minimize the po-
tential biases of longitudinal observational studies. This study confirms cost-effec-
tiveness of statin therapy for secondary prevention in real-life settings and sug-
gests further investigations on adherence effects.
PODIUM SESSION III:
DRUG USE RESEARCH TO INFORM POLICY DECISION MAKING
DU1
A TIME SERIES ANALYSIS OF THE EFFECT OF THE CO-PAYMENT ON
PHARMACEUTICAL CONSUMPTION IN TWO ITALIAN REGIONS
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OBJECTIVES: Since 2001 in Italy several regions have introduced a fixed co-pay-
ment with some differences in the amount and exemptions. The aim of the study
was to assess, through a time-series analysis, the effect of the introduction of the
co-payment on pharmaceutical consumption, using, as case study, two Italian
regions: Piemonte and Puglia. METHODS: Monthly data between January 2000 and
December 2010 related to both public and private outpatient consumption were
used in the analysis. Public consumption data were obtained from AIFA’s Medi-
cines Utilisation Monitoring Centre (OsMeD); conversely, data on private consump-
tion were obtained as difference between the total consumption (private and pub-
lic) provided by IMS Health and public consumption. The data were expressed in
Defined Daily Doses (DDD) per 1000 inhabitants. A segmented regression analysis
was performed, controlling for the autocorrelation. RESULTS: In Piemonte Region
the introduction of co-payment had an immediate significant effect on public con-
sumption with a reduction of 74 DDD per 1000 inhabitants (p-value 0.007). The
private consumption showed a significant increase of 119 DDD per 1000 inhabit-
ants (p-value 0.03) after the introduction of the co-payment. In Puglia Region the
co-payment didn’t have the expected outcome; in fact both public and private
consumption increased after the intervention. In the long term the public con-
sumption steadily grew and there was a significant reduction in private
consumption. CONCLUSIONS: The introduction of co-payment didn’t have the
expected effect in reducing the over consumption. In Piemonte Region the reduc-
tion of public consumption was balanced by the increase in private consumption
(substitution effect). In Puglia Region the co-payment resulted in a lowering of private
consumption, probably due to fewer available economic resources (income effect),
and didn’t have any effect on public consumption.
DU2
CONTRIBUTION OF PROLONGED-RELEASE MELATONIN AND ANTI-
BENZODIAZEPINE CAMPAIGNS TO THE REDUCTION OF BENZODIAZEPINE AND
Z-DRUG CONSUMPTION IN NINE EUROPEAN COUNTRIES
Clay E1, Falissard B2, Moore N3, Toumi M4
1Creativ-Ceutical, Paris, France, 2INSERM U-669 PSIGIAM, Paris, France, 3University of
Bordeaux, Bordeaux, France, 4University Claude Bernard Lyon, Lyon, France
OBJECTIVES: Insomnia is mostly treated by benzodiazepine (BZD) or Z-drugs that
are efficacious but are also associated with safety issues like dependence and re-
bound insomnia. These safety concerns may present a major public health issue,
particularly for the elderly. Prolonged-release (PR) melatonin is a non-sedative
hypnotic that has demonstrated clinically relevant efficacy on quality of sleep and
morning alertness, with a good safety profile. Several clinical trials demonstrated
that the PR-melatonin could help reduce BZD/Z-drugs consumption. The objective
is to analyze the impact of anti-BZD/Z-drug campaigns and the availability of PR-
melatonin on the consumption of BZD/Z-drugs. METHODS: Nine European coun-
tries were studied. For each one, we studied the evolution of BZD/Z-drug sales
volumes related to: the launch strategy of PR-melatonin, anti-BZD/Z drug cam-
paigns, the market uptake of PR-melatonin and its reimbursement status. The
sales differences from 2005 were interpreted graphically for BZD, Z-drugs and
PR-melatonin. RESULTS: Three types of countries were identified: -Countries
where the sales of BZD/Z-drugs decreased since 2007: Greece, Finland and Den-
mark. - Countries where the sales of BZD decreased while Z-drugs increased: Nor-
way, the Netherlands and the UK. The anti-BZD campaigns seem effective for
BZDs, but essentially resulted in the shift in prescription patterns towards Z-drugs.
- Countries where the sales of BZD were stable and Z-drugs increased resulting in
an overall increase in BZD/Z-drug sales despite anti-BZD/Z campaigns: France,
Sweden and Spain. Campaigns aiming to reduce the use of BZD/Z-drugs failed
when they were not associated with the availability and market uptake of PR-
melatonin. The reimbursement of PR-melatonin supports better penetration rates
and a higher reduction in sales for BZD/Z-drugs. The disreimbursement of BZD/Z-
drugs did not have any effect on Z-drug prescriptions, with an increase noted
during 2011. CONCLUSIONS: Policy makers wishing to change drug utilization pat-
terns should consider the availability of pharmacological alternatives.
DU3
MARKET ACCESS DELAYS FOR CNS DRUGS IN EUROPE
Flostrand SJA1, Anderson L2, Esposito G3
1IMS Consulting Group, Puteaux, France, 2IMS Consulting Group, London, UK, 3H. Lundbeck A/S,
Copenhagen, Denmark
OBJECTIVES: A recent study[1] by the Tufts Center for the Study of Drug Develop-
ment indicated that Central Nervous System (CNS) drugs take 35% longer to de-
velop and are less likely to gain approval compared to other new prescription
medicines. Once approved in Europe, Transparency Directive 89/105/EEC requires
countries to determine pricing and reimbursement (P&R) within 180 days but this
target is not always met. This study evaluated the time required to achieve P&R and
to launch CNS products in Europe to quantify how such delays impact patients and
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